Phase Ⅰ Study Of CNTO 95,A Fully Human Monoclonal Antibody （Mab） To αv Integrins,In Patients With Solid Tumors
作者单位：Department of Medical Oncology Christie HospitalManchesterUK Department of Medical Oncology Christie HospitalManchesterUK Department of Medical Oncology Christie HospitalManchesterUK Department of Medical Oncology Christie HospitalManchesterUK Department of Medical Oncology Christie HospitalManchesterUK Dept Neuroradiology University of Manchester Dept Neuroradiology University of Manchester Dept Neuroradiology University of Manchester Dept. Medical Physics Christie Hospital Clinical Research Oncology Centocor Inc.MalvernPAUSA Clinical Phannacology Centocor Inc.MalvernPAUSA Discovery Research Centocor Inc.MalvernPAUSA Clinical Pharmacology Centocor Inc.MalvernPAUSA Clinical Research Oncology Centocor Inc.MalvernPAUSA
会议名称：《第四届中国肿瘤学术大会暨第五届海峡两岸肿瘤学术会议》
会议日期：2006年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：正INTRODUCTION CNTO 95 is a fully human monoclonal antibody that binds and inhibits the av integrins, αvβ3 and αvβ5 with high affinity and also binds to αvβ1 and αvβ6. CNTO 95 inhibits cell adhesion, migration, proliferation and invasion of both tumor cells and endothelial cells in vitro. The antibody inhibits the αvβ3 and αvβ5 integrins that have been implicated in angiogenesis: While αvβ3 is involved in the response to FGF2 and TNFα, αvβ5 is implicated in VEGF and TGFα signaling. Correspondingly CNTO 95 inhibited tumor growth by approximately 80% （p = 0.0005） in a nude mouse